Javelin Biotech today announced it appointed Jacques Banchereau as chief scientific officer, effective immediately. Banchereau has more than 35 years of experience in academic and industrial research. He has held roles such as Professor and Director of Immunological Sciences at the Jackson Laboratory for Genomic Medicine, Chief Scientific Officer at Hoffman-La Roche, CSO at Immunai,…
KBI Biopharma names new chief business officer
KBI Biopharma this week announced it appointed Jean-Baptiste Agnus as chief business officer, effective immediately. Angus has more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates, and cell and gene therapies. As chief business officer, Angus will lead KBI’s…
Kintara Therapeutics, TuHURA to merge in all-stock transaction
Kintara Therapeutics and TuHURA recently announced they entered into a definitive merger agreement. The agreement is an all-stock transaction that will form a company with the expertise and resources needed to advance a risk-diversified late-stage oncology pipeline. The transaction is expected to close in Q3 2024. Kintara Therapeutics is a biopharmaceutical company investigating REM-001 in…
Aculys Pharma appoints new CEO
Aculys Pharma this week announced it appointed Hidemasa Tankgaki as CEO. Tanigaki replaces Takeshi Takahashi, who stepped down as the interim CEO and will remain a board member at the company. The appointment took effect on March 29. He has been a leader in the pharmaceutical industry for over 30 years, most recently leading the…
Lantheus announces a new CEO
Radiopharmaceutical-focused Lantheus Holdings (NASDAQ: LNTH) announced today that current board chair and industry veteran Brian Markison will become the company’s CEO, effective March 1. Markison succeeds Mary Anne Heino, who is retiring from Lantheus’ corner office after leading the company for nine years. Heino will serve as board chair after March 1. Board member Julie…
Forecast 2024: Pharma industry grapples with regulatory hurdles and AI opportunities
Heading into 2024, the pharma industry finds itself in uncharted waters. On the one hand, the sector’s commitment to R&D investment and innovation output is likely to remain strong, with tools based on AI, automation and real-world data promising more streamlined drug candidate optimization. Additionally, the pharma sector is typically resilient in economic downturns. Financial…
Navigating the new regulatory terrain pharma companies face with IRA and 340B
The ever-evolving landscape of pharmaceutical regulations has long been challenging to navigate, but now pharma companies face additional complexities with the introduction of the Inflation Reduction Act (IRA) and the ongoing implementation of the 340B drug pricing program. In recent years, the IRA has made waves for its impact on the pharmaceutical industry, including proposals…
Embracing change management in pharmaceutical sales: Ensuring smooth transitions amidst industry evolution
Embracing change management in pharmaceutical sales has become an essential competency for sales leaders. As a sales performance consultant who has worked with pharmaceutical and life sciences companies for over two decades, I’ve seen firsthand how the pace and frequency of change within pharma organizations has rapidly accelerated, making adaptation a constant requirement. Pharmaceutical sales…
Lilly reshuffles leadership deck
Lilly has announced that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of the year after 34 years with the company. The segment has been a key growth driver for the company and Lilly’s tirzepatide in particular has significant revenue growth potential. Lilly’s foray into the…